Gabriel G Malouf
Overview
Explore the profile of Gabriel G Malouf including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
74
Citations
1688
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lu X, Vano Y, Su X, Verkarre V, Sun C, Cheng W, et al.
J Immunother Cancer
. 2025 Jan;
13(1).
PMID: 39848689
Background: Endogenous retrovirus (ERV) elements are genomic footprints of ancestral retroviral infections within the human genome. While the dysregulation of ERV transcription has been linked to immune cell infiltration in...
2.
Bessac D, Baltzinger P, Poterszman N, Pham Van F, Collen C, Malouf G, et al.
Endocrine
. 2024 Dec;
87(3):1333-1341.
PMID: 39714577
Purpose: To evaluate organ-specific response to [Lu]DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) in patients with small intestine neuroendocrine tumor (SiNET) through [Ga]DOTATOC PET/CT, and to analyze tumor uptake and functional...
3.
Gantzer J, Severac F, Malouf G
Cancer
. 2024 Aug;
130(22):3936.
PMID: 39136251
No abstract available.
4.
Gantzer J, Toulmonde M, Severac F, Chamseddine A, Charon-Barra C, Vinson C, et al.
Cancer
. 2024 Mar;
130(13):2304-2314.
PMID: 38470379
Background: Perivascular epithelioid cell neoplasms (PEComas) encompass a heterogeneous family of mesenchymal tumors. Previously described clinicopathologic features aimed at distinguishing benign from malignant variants but lacked prognostic value. Methods: This...
5.
Su X, Lu X, Bazai S, Dainese L, Verschuur A, Dumont B, et al.
Nat Commun
. 2023 Nov;
14(1):7884.
PMID: 38036539
Wilms tumors are highly curable in up to 90% of cases with a combination of surgery and radio-chemotherapy, but treatment-resistant types such as diffuse anaplastic Wilms tumors pose significant therapeutic...
6.
Lu X, Vano Y, Su X, Helleux A, Lindner V, Mouawad R, et al.
Cell Rep Med
. 2023 Nov;
4(11):101287.
PMID: 37967556
The efficacy of immune checkpoint inhibitors varies in clear-cell renal cell carcinoma (ccRCC), with notable primary resistance among patients. Here, we integrate epigenetic (DNA methylation) and transcriptome data to identify...
7.
Davidson G, Helleux A, Vano Y, Lindner V, Fattori A, Cerciat M, et al.
Cancer Res
. 2023 Jun;
83(17):2952-2969.
PMID: 37335139
Significance: Single-cell and spatial transcriptomics reveal the proximity of mesenchymal tumor cells to myofibroblastic cancer-associated fibroblasts and their association with disease outcome and immune checkpoint inhibitor response in clear cell...
8.
Lu X, Tawanaie Pour Sedehi N, Su X, Yan F, Alhalabi O, Tannir N, et al.
Oncologist
. 2023 Jun;
28(11):1009-1013.
PMID: 37315151
Racial disparities have been documented in the biology and outcome of certain renal cell carcinomas (RCCs) among Black patients. However, little is known about racial differences in MiT family translocation...
9.
Vokshi B, Davidson G, Tawanaie Pour Sedehi N, Helleux A, Rippinger M, Haller A, et al.
Nat Commun
. 2023 May;
14(1):3034.
PMID: 37236926
Renal medullary carcinoma (RMC) is an aggressive tumour driven by bi-allelic loss of SMARCB1 and tightly associated with sickle cell trait. However, the cell-of-origin and oncogenic mechanism remain poorly understood....
10.
Alhalabi O, Thouvenin J, Negrier S, Vano Y, Campedel L, Hasanov E, et al.
Oncologist
. 2023 Jan;
28(5):433-439.
PMID: 36640141
Background: There remains a paucity of data regarding the efficacy of immune checkpoint therapy (ICT) combinations ± vascular endothelial growth factor (VEGF) targeted therapy (TT) in translocation renal cell carcinoma...